Guided Therapeutics (GTHP) Cost of Revenue (2016 - 2025)
Historic Cost of Revenue for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to $25000.0.
- Guided Therapeutics' Cost of Revenue fell 6710.53% to $25000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $218000.0, marking a year-over-year decrease of 2296.82%. This contributed to the annual value of $287000.0 for FY2024, which is 708.96% up from last year.
- As of Q3 2025, Guided Therapeutics' Cost of Revenue stood at $25000.0, which was down 6710.53% from $51000.0 recorded in Q2 2025.
- In the past 5 years, Guided Therapeutics' Cost of Revenue registered a high of $76000.0 during Q3 2024, and its lowest value of $25000.0 during Q3 2025.
- For the 5-year period, Guided Therapeutics' Cost of Revenue averaged around $54052.6, with its median value being $52000.0 (2022).
- In the last 5 years, Guided Therapeutics' Cost of Revenue soared by 8250.0% in 2023 and then plummeted by 6710.53% in 2025.
- Guided Therapeutics' Cost of Revenue (Quarter) stood at $34000.0 in 2021, then skyrocketed by 52.94% to $52000.0 in 2022, then increased by 25.0% to $65000.0 in 2023, then grew by 6.15% to $69000.0 in 2024, then plummeted by 63.77% to $25000.0 in 2025.
- Its Cost of Revenue was $25000.0 in Q3 2025, compared to $51000.0 in Q2 2025 and $73000.0 in Q1 2025.